Carboplatin, an active drug in advanced head and neck cancer.

Abstract

Because of the clinical activity of carboplatin in several types of tumors, this drug was studied in a phase II trial of 25 patients with advanced head and neck cancer [stage IV (M0)] without prior treatment. Six patients (24%) achieved objective response, including two patients with complete response. Carboplatin toxicity was mild in most patients, with nausea, vomiting, and myelosuppression being the most frequent side effects. No renal or neurologic toxicity was observed. Further trials of carboplatin in advanced head and neck cancer are warranted.

• Authors: L de Andres Basauri, A Lopez Pousa, E Alba, F Sampedro
• Journal: Cancer treatment reports (Cancer Treat Rep) Vol. 70 Issue 10 Pg. 1173-6 (Oct 1986) ISSN: 0361-5960 [Print] United States
• PMID: 3530443 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Antineoplastic Agents
• Organoplatinum Compounds
• Carboplatin

Topics

• Adult
• Aged
• Antineoplastic Agents (adverse effects, therapeutic use)
• Carboplatin
• Carcinoma, Squamous Cell (blood, drug therapy, pathology)
• Clinical Trials as Topic
• Drug Evaluation
• Head and Neck Neoplasms (blood, drug therapy, pathology)
• Hematologic Diseases (chemically induced)
• Humans
• Middle Aged
• Neoplasm Staging
• Organoplatinum Compounds (adverse effects, therapeutic use)